Pharmacophore

ISSN-2229-5402

Journal home page: http://www.pharmacophorejournal.com

LIPID-POLYMER BASED NANOPARTICLES AS A NEW GENERATION THERAPEUTIC DELIVERY PLATFORM FOR ULCERATIVE COLITIS IN VITRO/IN VIVO EVALUATION

Birendra Shrivastava[1]*, K. Venkata Gopaiah[2, 3], G. Sudhakara Rao[4]

1. ***Principal & Professor, Jaipur National University, Jaipur, India.***
2. ***Research Scholar, Jaipur National University, Jaipur, India.***
3. ***Koneru Lakshamaiah Education Foundation, K L College of Pharmacy, Vaddeswaram, Guntur-A.P, India.***
4. ***Vishwa Bharathi College Of Pharmaceutical Sciences, Guntur-A.P., India.***

ARTICLE INFO

Received:
22th Mar 2019
Received in revised form:
18th Jul 2019
Accepted:
22th Jul 2019
Available online:
28th Aug 2019

Keywords: *Novel Drug Delivery systems, Ulcerative colitis, Nanoparticles, Nanocrystalline suspensions.*

ABSTRACT

The headway of the new medication organization frameworks (NDDS) was a theme of extraordinary enthusiasm for a large number of the pharmaceutical organizations since the advancement of the new particle forced a critical consumption of capital, HR and expert experience. Irritation in the digestive tract is called IBD. Ulcerative colitis (UC) and Crohn's infection were regularly called provocative gut sickness (IBD). Lipid nanoparticles (NC) were nanocrystalline suspensions, encased by lipids that are strong at room temperature. NCs are innovative of nanoparticle transporters, notwithstanding common ones, for example, liposomes, lipid emulsions, and polymeric nanoparticles. The NCs were set up by the hot homogenization technique utilizing an assortment of extents of stearic corrosive and triglyceride monostearate, and Budesonide was picked as the model medication for the NC readiness. Guar gum was picked as a polysaccharide for the planning of NC. The readied NCs portrayed by molecule estimate, polydispersity file, surface charge, shape and surface morphology, embodiment productivity and in vitro examinations were performed in different disintegration media. The extra chosen F6 definition was completed for in vitro discharge energy, and in vivo strength examinations. The investigation started with preformulation contemplates on the chosen medication. A few parameters were contemplated, including bright (UV) absorbance, infrared range, liquefying point, solvency studies and differential checking calorimetry (DSC). The NC arrangement process was effectively reached out on a research facility scale, demonstrated simple execution and took into consideration a reproducible scattering of NC as far as molecule estimate, embodiment productivity, stacking effectiveness, polydispersity record, and surface morphology by SEM and TEM. Discharge ponders within sight of rodent cecal substance indicated more prominent medication discharge at 24 hours of disintegration, which was very different from the medication discharged without rodent cecal substance. It was because of the corruption of guar gum within sight of rodent cecal substance. The in vitro discharge energy examined in the F6 detailing. The detailing indicated Korse-Meyer-Peppas as a best-fit model and pursues the vehicle of Super Case-II. The results of in vivo studies revealed that lipid nanoparticles were the most advisable for colon-specific drug delivery of Budesonide. It ensures that lipid nanoparticles would be therapeutically useful in the colonic region.

To Cite This Article: Birendra Shrivastava, K. Venkata Gopaiah, G. Sudhakara Rao, (2019), "*Lipid-Polymer Based Nanoparticles as a New Generation Therapeutic Delivery Platform for Ulcerative Colitis in Vitro/In Vivo Evaluation*", ***Pharmacophore, 10(4),*** *15-27.*

Introduction

Anatomy of Colon

The stomach related tract is the organ framework inside multicellular creatures that ingest sustenance, digest it to separate vitality and supplements and remove the remining waste. The principle elements of the GI tract are ingestion, assimilation and poop. In an ordinary grown-up male, the GIT is around 6.5 meters (20 feet long) and comprises of upper and lower GI tracts. The upper GI tract is framed by the mouth, pharynx, throat and stomach. The lower GI tract incorporates the small digestive system, the internal organ, and the butt. A digestive organ is more extensive and shorter than the small digestive tract (roughly 1.5 meters long, contrasted with 6.7 with 7.6 meters long for the small digestive system) [1]. The colon is 1.5 cm long and comprises of the cecum, the rising colon, the hepatic flexure, the transverse colon, the splenic flexure, the sliding colon and the sigmoid colon. The auxiliary qualities spoke to are in the accompanying figure.

Corresponding Author: Birendra Shrivastava, Professor & Principal, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan-India, Contact no - 09966337164. Email: venkatgopi8789 @ gmail.com



Figure 1: [2]

Anatomical features of the small intestine and large intestine:

Organ Characteristics

Small Intestine

- Duodenum
- Jejunum
- Ileum

Large Intestine [3, 4]

- Caecum
- Ascending colon
- Hepatic flexure
- Transverse colon
- Descending colon
- Sigmoid colon
- Rectum

TYPES OF NLC [5]:

It is outstanding from the investigation of suppositories that exceedingly requested crystalline lipid lattices will prompt the ejection of the medication. Nanoparticles and lipid microparticles produced using blends of strong lipids may encounter this, particularly when the nanoparticles are set up from exceptionally sanitized lipids, for instance, tristearin. The arrangement of very arranged alterations, especially amid capacity, little space for medication atoms and ejection of medications prompts sedate precious stones in suspensions and strong dose shapes. To keep away from the issue, the particles must have a controlled nanostructure that offers enough space to oblige the medicine. Various methodologies were taken for an improved NLC nanostructure [6].

- **Type I**
- **Type II**
- **Type III**

Methods Employed in Fabrication of Nlcs [7]

There are several methods for the preparation of lipid nanoparticulate DDS. In this type of DDS the drug mainly depends on solubility and stability, the lipid matrix, route of administration, etc.,

- High-pressure homogenization
  a) Hot high-pressure homogenization
  b) Cold high-pressure homogenization
- Microemulsion technique [8, 9]
- Solvent emulsification-evaporation technique
- Solvent emulsification-diffusion technique
- Phase inversion temperature (PIT) method
- Melting dispersion method:
- High Shear homogenization or ultrasonication technique
- Solvent injection (or solvent displacement) technique
- Double emulsion

Strategies employed for overcoming the issues related to the stability of NLCs [10, 11]

- Spray drying
- Lyophilization
- Stabilizing agent
  A) Poloxamers
  B) Polyethylene glycol

Aim and Objectives:

The point is to answer the issue of early colonic arrival of the medication in the treatment of ulcerative colitis. Because of its potential restorative advantages, more prominent bioavailability and fewer symptoms, the framework dependent on nano bearers picked the advancement of the plan. The target of the proposed work is to plan, enhance and portray another drug organization framework dependent on polysaccharides to deliver the issues identified with prescriptions and treatment through the advancement of controlled medicine organization frameworks. The accompanying destinations are incorporated into the present work to survive:

1. Dissolvability issues.
2. Penetrability issues.
3. Non-uniform circulation of meds.
4. Inquiries concerning the significant potential.

A critical zone in which scholarly research has as of late centered is to create nanostructured lipid transporters focusing on ulcerative colitis. Numerous methodologies have been made to speak to aggravated ulcerative colitis. The fundamental reason for the flow investigate work is to plan nanocarriers stacked with coordinated budesonide. The organization of focus on medications has turned out to be progressively significant not just for the organization of medications for the treatment of nearby illnesses related with the colon, for example, Crohn's infection, ulcerative colitis, touchy inside disorder, yet also for potential advantages for the first supply of proteins. The most basic test in this way to deal with medication conveyance is to protect the plan amid its section through the stomach and into the initial six meters of the small digestive system. Traditional medication conveyance frameworks [12] are not fruitful when connected to the treatment of ulcerative colitis (UC) because of deficient medication affidavit at the site of activity. Consequently, an incredible exertion has been made to create nano-sized particles that gather in nervous colonic tissues because of their inclination to mucoadhesion, which thus advances cell take-up and intracellular amassing of the medication. What is more, this is relied upon to improve penetrability and could likewise address the bioavailability issues of such drugs. The arrival of polysaccharide-based medications in the colon, together with a pH-subordinate polymer and furthermore the utilization of prebiotics, improve the pharmacological activity of the medications [13].

Experimental Materials & Methods: [14]

Drug & Chemicals

The active budesonide material was obtained from Sigma Aldrich, India. Hydrochloric corrosive, potassium dihydrogen phosphate, and sodium dihydrogen orthophosphate were obtained from SD Fine Chemicals Limited, India.

In vitro medication discharge considers in pH cradle media [15]

The in vitro investigation of medication discharge was performed by the dialysis strategy. In any case, a slight modification was made in the system. The medication discharge tests were completed in three dialysis sacks (MWCO 6-8 kDa) which drenched in 50 ml bird of prey tubes containing the disintegration medium. 400 µl of detailing (proportionate to 2 mg of budesonide) was put in each sack containing 40 ml of HCl cushion (pH 1.2) at 37 ± 0.5 ° C for 2 hours at 100 rpm. Following 2 hours, the pH was changed to 6.8 (pH of the small digestive tract) utilizing 1N sodium hydroxide arrangements. Samples of about 1.0 ml were pulled back at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 9.0, 12.0, 15.0, 18.0, 21.0 and 24.0 h separately of the disintegration medium and were supplanted by the new cradle medium. The separated arrangements were sifted utilizing 0.22 µ layer channels and examined utilizing RP-HPLC at 230 nm. Each investigation was rehashed multiple times, and the normal information was recorded.

In vitro medication discharge considers in cecal media of rodents [16, 17]

The in vitro investigation of medication discharge was performed by the dialysis technique. A slight change in the methodology was done. The medication discharge tests were done in three dialysis sacks (MWCO 6-8 kDa) which drenched in 50 ml bird of prey tubes containing the disintegration medium. 400 µl of definition (proportionate to 2 mg of budesonide) put in each sack containing 40 ml of HCl support (pH 1.2) at 37 ± 0.5 ° C for 2 hours at 100 rpm. After 2 hours, the pH was changed to 6.8 (pH of the small digestive tract) utilizing 1N sodium hydroxide arrangements. Toward the finish of the fifth hour, the medium was degassed utilizing nitrogen gas to evacuate undissolved oxygen to keep up anaerobic conditions inside the vehicle for 15 minutes. Rodent cecal arrangement newly arranged at 4% w/v was added to the disintegration medium, and the examination was proceeded for 24 h under nonstop nitrogen cleansing all through the investigation.

Samples of about 1.0 ml were pulled back at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 9.0, 12.0, 15.0, 18.0, 21.0 and 24.0 h separately of the disintegration medium and were supplanted by the new support medium. The separated arrangements were sifted utilizing

0.22 µ layer channels and investigated utilizing RP-HPLC at 230 nm. Each investigation was rehashed multiple times, and the normal information was recorded.

In vitro medication discharge examinations in human fecal media [18, 19]

The in vitro investigation of medication discharge was performed by the dialysis technique. A slight change in the final strategy was done. The medication discharge tests were done in three dialysis sacks (MWCO 6-8 kDa) which submerged in 50 ml hawk tubes containing the disintegration medium. 400 µl of detailing (identical to 2 mg of Budesonide) set in each sack containing 40 ml of HCl cushion (pH 1.2) at 37 ± 0.5 ° C for 2 hours at 100 rpm. After 2 hours, the pH was changed to 6.8 (pH of the small digestive system) utilizing 1N sodium hydroxide arrangements. Toward the finish of the fifth hour, the medium was degassed utilizing carbon dioxide gas to expel undissolved oxygen and keep up anaerobic conditions inside the mode for 15 minutes. At that point, 5% w/v of newly arranged fecal suspensions homogenized in the disintegration medium, and the examination was proceeded up to 24 h under persistent CO_2 cleansing all through the investigation. Samples of about 1.0 ml were pulled back at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 9.0, 12.0, 15.0, 18.0, 21.0 and 24.0 h separately of the disintegration medium and were supplanted by the new support medium. The extricated arrangements were sifted utilizing 0.22 µ layer channels and investigated utilizing RP-HPLC at 230 nm. Each investigation was rehashed multiple times, and the normal information was recorded. [20]

Transient dependability ponders.

In vivo investigations

Assessment of colon aggravation [5, 21]

Each of the creatures utilized in the investigation was housed in clear sans pathogen conditions, and analyses was done by institutional aides. BALB/c mice somewhere in the range of 8 and 12 weeks of age got from a creature care focus at the University Clinic of Erlangen. Every single creature explore performed by the German creature.

Prior to enlistment of colitis, all mice were gauged and affirmed to be sound. For the acceptance of colitis, the most normally utilized compound specialists, for example, TNBS, DSS or oxazolone, were utilized with a change of the convention depicted previously. The creature was assembled into four subgroups, one group of mice stayed as untreated control, one treated with a free medication arrangement, one group treated with straightforward GUARGUM nanoparticles and another treated with covered GUARGUM nanoparticles. Each treated group got an equivalent portion of budesonide (portion: 0.168 mg/kg) as a free medication arrangement or oral suspension of nanoparticles.

In vivo pictures of mice [7, 22]

For the in vivo picture of the colitis action, the IVIS 100 imaging framework was utilized, comprising a conservative camera equiped with a cooled CCD camera. The luminescent test L-012 (Wako Chemical) was done in sterile H_2O to a last convergence of 20 mol. L-012 was managed intraperitoneally in an infusion volume of 100 µl. Amid in vivo imaging, the mice were immobilized after the organization of iso fluran (1.5%). The presentation times of the picture were somewhere in the range of 1 and 2 minutes, contingent upon the power of the flag. The light outflow of the area of intrigue was measured as photons/second cm^2/steradian. Tissue samples were acquired from all treated and untreated groups, and recoloring was performed by an invulnerable histochemistry procedure. In the first place, colon cryosections were fixed by PFA and afterward recoloring of myeloperoxidase positive cells was performed utilizing a rodent monoclonal counter acting agent for MPO (Thermo Scienti fi c) at a grouping of 1: 100 and brooding for 10 hours at 4 °. . C. Hence, the slides were brooded with an auxiliary jackass hostile to rabbit immunizer conjugated with Cy3 (Bio Legend), at a centralization of 1: 200. Cores were recolored with Hoechst 33342 (Life Technologies).

Results and Discussion:

It was seen from the FTIR range of the physical blend of budesonide with Guargum, stearic corrosive and glycerol monostearate as appeared in the figure, that every one of the pinnacles of utilitarian groups, for example, the OH extend, the sweet-smelling CH extend, The C extend, the OH carboxyl stretch, the CO carboxyl stretch and the NH flexion of the budesonide bunches were recorded at 3085 cm^{-1}, 2982 cm^{-1}, 1650 cm^{-1}, 2552 cm^{-1}, 1314 cm^{-1} and 1620 cm^{-1} separately. The characteristic peaks of the budesonide maintained in the spectra from the distinctive peaks of excipients. Thus, no interaction was observed between the budesonide and the excipient in the physical mixture of drug and excipients.



Figure 2: FTIR of a physical mixture of excipients with Budesonide

Differential Scanning Calorimetry (DSC)

The peaks for Budesonide at 281°C, 286°C, and 284°C respectively.



Figure 3: DSC of a mixture of excipients with Budesonide

Formulation Development

The goal of this exploration was to create NC for the restriction of a medication in the colon. NCs are strong lipid lattices that trap the medication in its crystalline structure. These are broadly utilized in the conveyance of the medication. Since they are biodegradable, they have sufficient soundness and noteworthy danger because of the nonattendance of natural solvents. Budesonide is chosen as a model medication in the plan of the NC. Budesonide was picked as a model medication for the readiness of NC. 2 ml of plan was arranged for every detailing group (F1 to F8). Reasonable measures of triglyceride monostearate, stearic corrosive, guar gum of various arranged fixations were used. The NCs procured are portrayed.

Table No. 01: Formulation Models

Excipients	F1	F2	F3	F4	F5	F6	F7	F8
Budesonide (mg)	10	10	10	10	10	10	10	10
Triglyceride monostearate (mg)	30	50	70	50	50	50	50	50
Stearic acid (mg)	70	50	30	50	50	50	50	50
Polysorbate 80 (µl)	20	20	20	20	20	20	20	20
Milli-Q water (µl)	1980	1980	1980	---	---	---	---	---
Guargum (0.2%w/v) (µl)	---	---	---	1980	---	---	---	---
Guargum (0.3%w/v) (µl	---	---	---	---	1980	---	---	---

Guargum (0.4%w/v) (µl)	---	---	---	---	---	1980	---	---
Guargum (0.5%w/v) (µl)	---	---	---	---	---	---	1980	---
Guargum (0.6%w/v) (µl)	---	---	---	---	---	---	---	1980

Particles size determination

The particle sizes of the NCs were displayed in the table 2.

Table No. 02 -Particle size of Nanoparticles

S. No.	Formulation codes	Particle size (nm)
1	F1	135±0.7
2	F2	127±0.4
3	F3	131±0.8
4	F4	210±0.3
5	F5	214±0.5
6	F6	217±0.6
7	F7	268±0.2
8	F8	341±0.2



Figure 4: Size distribution intensity of uncoated nanoparticles



Figure 5: Size distribution intensity of coated nanoparticles

Surface charge of the determination of the particle by Zeta Seizer

TABLE NO. 03: Zeta potential of nanoparticles

S.No.	Formulation Code	Zeta Potential (mV)
1	F2	-8.6
2	F5	-29.7
3	F6	-34.7
4	F7	-31.4



Figure 6: Zeta potential distribution of F2 Formulation



Figure 7: Zeta potential distribution of F5 Formulation



Figure 8: Zeta potential distribution of F6 Formulation



Figure 9: Zeta potential distribution of F7 Formulation

Surface morphology by SEM

The arranged examples were seen under an examining electron magnifying instrument (SEM-Joel, JSM-6100). SEM and TEM give an approach to straightforwardly watch nanoparticles, physical portrayal of nanoparticles for morphological examination. It was discovered that the state of the particles is round with a size scope of 400-500 nm. The SEMs of guar gum nanoparticles stacked with budesonide of details F2, F4, F5, F6, F7 and F8 were practically round in the efficiency figures of the particles.

Drug encapsulation efficiency, loading efficiency, and Polydispersity Index determination

TABLE NO-04: Particle size, Encapsulation efficiency and Polydispersity of Nanoparticles

Formulation codes	Particle size (nm)	Encapsulation efficiency	Polydispersity Index	Loading efficiency
F1	135±0.7	61.26±0.5%	0.423±0.04	1.10±0.5%.
F2	127±0.4	65.38±1.2%	0.382±0.02	1.17±0.1%.
F3	131±0.8	63.24±1.1%	0.451±0.01	1.12±0.6%.
F4	210±0.3	62.38±0.4%	0.512±0.02	1.15±0.7%.
F5	214±0.5	64.28±0.3%	0.501±0.03	1.18±0.2%.
F6	217±0.6	72.71±1.2%	0.340±0.04	1.27±0.4%.
F7	268±0.2	63.31±1.1%	0.522±0.05	1.12±0.1%.
F8	341±0.2	56.38±3.1%	0.623±0.07	1.09±0.2%.

Fourier Transform infrared spectroscopy (FTIR)

The FTIR spectra exhibited in the figure of the developed NCs reveals the characteristic peaks of functional groups of drug Budesonide. The results indicate the absence of any interaction of the drug with excipient during the preparation of NCs.



Figure 10: FTIR of Formulation F2



Figure 11: FTIR of Formulation F6



Figure 12: FTIR of Formulation F7

Differential Scanning Calorimetry (DSC)

From the DSC thermogram, it was clear that charged budesonide stacked NCs demonstrated an endothermic top at 279 °C and the endothermic end set up the guar gum top stacked with lyophilized budesonide containing NC at 257 °C individually. The decline in softening pinnacles of budesonide in lyophilized NCs proposes a conceivable lessening in the crystallinity of budesonide in nanoparticles (167). The lessening in the begin and the most extreme temperature connected with the dissolve of budesonide can be set apart because of the decrease in molecule estimate and the comparable to increment in the surface region. This effect on enthalpy decrease of the combination, when associated with bigger particles, require more vitality to overpower the quality of the system. Comparable outcomes were watched propelling the 5FU nanoparticles utilizing grouped lipids.



Figure 13: DSC of Formulation F7



Figure 14: DSC of Formulation F2



Figure 15: DSC of Formulation F6

Medication discharge is considered in various media: it was very certain that the disintegration profile demonstrates a generous arrival of budesonide from NC stacked with budesonide in cecal media of rodents related with two other media (human fecal medium and cradle). Bifidobacterium, Lactobacillus species and bactericides were the most transcendent microscopic organisms in the media that debased the guar gum covering, which set off the dynamic arrival of the medication in cecal rodent media contrasted with human fecal media and cushioned media.

TABLE NO. 05: A comparative *in-vitro* study of budesonide-NCs in Rat caecal media

Time (hr.)	F4 Formulation	F5 Formulation	F6 Formulation	F7 Formulation	F8 Formulation
0	0	0	0	0	0
2	0.6±0.4	0.6±0.2	0.6±0.2	0.6±0.2	0.6±0.2
3	11.8±1.4	10.8±1.4	2.5±0.6	2.3±0.4	2.2±1.4
5	25.2±2.0	24.2±2.7	7.8±2.0	7.6±1.8	7.2±1.8
6	32.1±1.4	31.6±2.1	21±2.7	19.4±2.3	16.4±2.4
9	41.6±2.1	39.4±3.4	31.1±2.8	30.5±2.1	25.5±1.3
12	49.6±2.0	48.2±2.4	48±3.0	37.4±1.6	32.4±1.6
15	62.1±2.6	61±2.3	60.4±2.8	44.2±2.1	38.2±2.4
18	78.4±1.2	77.4±1.4	76±1.8	50.1±1.4	44.1±1.4
21	86±2.2	85.2±1.2	84.1±1.8	58.4±2.3	50.4±1.3
24	89±1.5	88±1.6	87±2.0	65.2±3.1	59.2±2.1



Figure 16: A comparative *in-vitro* study of budesonide-NCs in Rat caecal media

***In vivo* studies**

Colitis models

Three settled creature models of colitis (DSS, TNBS and oxazolone) were chosen for in vivo examinations and the helpful viability of the free medication and the nanoparticles stacked with the investigated medication. After the enlistment of colitis, one group of creatures was kept up with aggravated mucosa for correlation, while different groups were treated with free budesonide, basic nanoparticles stacked with budesonide or nanoparticles covered with guar gum.

Myeloperoxidase activity



Figure 17: *In vitro* release of budesonide from plain and coated nanoparticles in simulated gastrointestinal fluid at pH 1.2 and 7.4.
(Mean, n = 3 ± SD)



Figure 18: *In vivo* MPO activity measurement in live mice by luminescence detection

Mini-endoscopic analysis

A second endoscopy think about was performed on the second day after the acceptance of irritation to check the manifestations of aggravation in live mice. The outcomes permitted the observing and arrangement of the malady, just as the colitis score. Kindled mice plainly demonstrated indications of irritation with exorbitant creation of bodily fluid and shallow granular mucosa.

Likewise, the endoscopy think about was additionally performed for all the treated groups. Based on these endoscopic indications of aggravation, a colitis score extending from 0 (no indications of irritation) to 10 (serious colitis) was created. The outcomes demonstrated that the covered Guargum nanoparticles performed superior to the single nanoparticles or the Guargum free medication arrangement and demonstrated the most reduced score in all colitis models. Every one of the information were gathered for examination by a Kruskal Wallis test to make numerous correlations and a huge measurable distinction. the outcomes demonstrated a dynamic abatement in the colitis score when treated with free budesonide; Guargum nanoparticles stacked with budesonide and covered.

What's more, the information uncovered that the group treated with free budesonide calmed the aggravation (* $p < 0.05$) when contrasted with the control of the fire. The group of creatures treated with basic Guargum nanoparticles stacked with budesonide demonstrated a lessening in irritation (** $p < 0.01$) when contrasted with free budesonide, while the group treated with nanoparticles covered with Guargum demonstrated a lower colitis score (*** $p < 0.001$) when contrasted with the group treated with Guargum nanoparticles and had a measurably critical distinction. The covered Guargum nanoparticles demonstrated a similarly better remedial movement because of their enteric covering which permits the conveyance of a most extreme measure of the medication stacked to the objective site without earlier misfortune in the stomach or other piece of the gastrointestinal tract after oral organization.

Healthy control inflamed control



(a) Inflamed colitis as control nanoparticles (b) Free budesonide treated (c) Treated with budesonide loaded plain

(d) Treated with budesonide loaded coated nanoparticles (e) Cross-sectional study by immune histochemical techniques where the coated nanoparticles showed the low extent of granulocytes.

Figure 19: Plain Guargum NP Guargum coated NP

Budesonide Solution

References

1. Rafael J A, Jabor JR, Casagrande R, Georgetti SR, Burin M F and Francesca M J V. Validation of DPPH and nitrosation methods for mesalazine determination in the pharmaceutical dosage form. Brazilian Journal of Pharmaceutical Sciences. 2007; 97-103.
2. Song YM, Xu JP, Ding L, Hou Q, Liu JW, Zhu ZL. Syntheses, characterization and biological activities of rare earth metal complexes with curcumin and 1,10-phenanthroline-5,6-dione. J Inorg Biochem. 2009; 103 (3): 396-400.
3. Rubinstein, A., Radai, R., Ezra, M., Pathak, S., Rokem, J.S. In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier, Pharm. Res., 1993; 10: 258-263.
4. Kotla, N.G., Singh, S., Maddiboyina, B., Omprakash, S., Webster, T. A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon-specific drug delivery system: an approach to alternative colon media. International Journal of Nanomedicine. 2016: 11:1089-1095.
5. Meyer E, Heinzelmann H. Scanning force microscopy. In: Wiesendanger R, Guntherodt HJ.Editors. Scanning tunneling microscopy II, Surface science. New York: Springer Verlag; 1992: 99-149.
6. Pooria Gill, Tahereh Tohidi Moghadam, and Bijan Ranjbar. Differential Scanning Calorimetry Techniques: Applications in Biology and Nanoscience. Journal of Biomolecular Tech. 2010; 21:167–193.
7. Chourasia MK, Jain SK, Soni V, Gupta Y. Crosslinked guar-gum microsphere: A viable approach for improved delivery of anticancer drugs for the treatment of colorectal cancer. AAPS Pharm. Sci. Tech 2006; 7: 44-52.

8. Sinha VR, Mittal BR, Bhutani KK, Rachna Kumria. Colonic drug delivery of 5-fluorouracil: an In vitro evaluation. Int. J. Pharm. 2004; 269:101-108.
9. Krishnaiah YSR, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS. Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int. J. Pharm. 2002; 236:43-55.
10. Nalini Kanta Sahoo, Madhusmita Sahu, Podilapu SrinivBudesonide Rao, and Goutam Ghosh. Validation of stability indicating RP-HPLC method for the estimation of Budesonide in bulk and tablet dosage form. Pharmaceutical Methods. 2013; 4: 56-61
11. Kotla, N.G., Gulati, M., Singh, S.K., Shivapooja, A. 'Facts, Fallacies and Future of Dissolution Testing ofPolysaccharide-Based Colon-Specific Drug Delivery.' Journal of Controlled Release. 2014: 178: 55–62.
12. Ghadially FN, Walley VM. Melanosis of the gastrointestinal tract. Histopathology. 1994; 25: 197-207.
13. Lofberg R. New steroids for inflammatory bowel disease. Inflamm bowel dis 1995; 1:135-41.
14. Muller R.H., Mader K., Gohla S. Lipid-based nanocarriers (NC'S) for controlled drug delivery: a review of state of the art. Eur J Pharm Biopharm 2000; 50: 161-177
15. Padilla-Carlin DJ, McMurray DN, Hickey AJ. The guinea pig as a model of infectious diseases. Comp Med. 2008; 58(4): 324-340.
16. Kotla, N.G., Shivapooja, A., Muthyala, J., Pinakin, P. 'Effect of Guar Gum and Xanthan Gum Compression Coating on Release Studies of Metronidazole in Human Faecal Media for Colon Targeted Drug Delivery System.' Asian Journal of Pharmaceutical and Clinical Research. 2013: 6 (2): 310-313.
17. Mathews BR. Regulatory aspects of stability testing in Europe. Drug Dev. Ind. Pharm 1999; 25: 831-856.
18. V. Venkateswarlu and K. Manjunath, Preparation, characterization and in-vitro release kinetics of clozapine Lipid-based nanocarriers, J. Control. Release. 2004; 95(3): 627–638.
19. Bhandari Rohit and Kaur Indu Pal. A Method to PrepareLipid-based nanocarriers with Improved Entrapment Efficiency of Hydrophilic Drugs. Current Nanoscience 2013; 9(2): 211-220.
20. Berardi R R. Inflammatory bowel disease. In: Herfindahl ET, Gourley D R, editors. Textbooks of therapeutics drug and disease management. 7th ed. Philadephia: Lippincoff Williams and Wilkins; P.533.
21. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: a systematic study of particle size and drug content. Int J Pharm. 2007; 336(2): 367-375.
22. Milojevic S, Newton JM, Cummings JH, et al. Amylose as a coating for drug delivery to the colon: Preparation and In vitro evaluation using 5-aminosalicylic acid pellets, J. Control. Release. 1996; 38:75-84.